The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: Behavioral and histological studies using two different dosages

Neuroscience Research

Volumn 36, Issue 4, 2000, Pages 319-325

  Aoi, Mizuho ^a   Date, Isao ^a   Tomita, Susumu ^a   Ohmoto, Takashi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

6 Hydroxydopamine (6 OHDA); Dopamine; Glial cell line derived neurotrophic factor (GDNF); Parkinson's disease; Striatum

Indexed keywords

APOMORPHINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BODY WEIGHT; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; HISTOLOGY; IMMUNOCYTOCHEMISTRY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; APOMORPHINE; AXONS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUNCTIONAL LATERALITY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; MOVEMENT; NEOSTRIATUM; NERVE DEGENERATION; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; WEIGHT LOSS;

EID: 0034074394     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-0102(00)00097-3     Document Type: Article

References (29)

1. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., Granholm A.C. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355:1995;479-489.
2. Cadet J.L., Zhu S.M. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res. 595:1992;316-326.
3. Chiueh C., Markey S.P., Burns R.S., Johanessen J., Pert A., Kopin I.J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur. J. Pharmacol. 100:1984;189-194.
4. Date I. Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: basic and clinical studies. Brain Res. Bull. 40:1996;1-19.
5. Date I., Felten D.L., Felten S.Y. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519:1990;266-276.
6. Date I., Shingo T., Ohmoto T., Emerich D.F. Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells. Exp. Neurol. 147:1997;10-17.
7. Date I., Aoi M., Tomita S., Collins F., Ohmoto T. GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. NeuroReport. 9:1998;2365-2369.
8. 3H]spiroperidol binding and rotational behavior in unilaterally 6-hydroxydopamine-lesioned rats. Brain Res. 211:1981;285-292.
9. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.F., Gerhardt G.A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:1994;107-111.
10. Hudson J., Horene C.G., Stromberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., Gerhardt G.A. Correlation of apomorphine-and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626:1993;167-174.
11. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:1995;104-111.
12. Lapchak P.A., Jiao S., Miller P.J., Williams L.R., Cummins V., Inouye G., Matheson C.R., Yan Q. Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tiss. Res. 286:1996;179-189.
13. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
14. Olson L., Backlund E.O., Ebendal T., Freedman R., Hamberger B., Hansson P., Hoffer B., Lindblom U., Meyerson B., Stromberg I. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. Arch. Neurol. 48:1991;373-381.
15. Opacka-Juffry J., Ashworth S., Hume S.P., Martin D., Brooks D.J., Blunt S.B. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. NeuroReport. 7:1995;348-352.
16. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1997;Academic Press, New York.
17. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
18. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 82:1998;129-137.
19. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
20. Schneider J.S., Peacock V. Differential effects of GDNF treatment on rotational asymmetry, skilled forelimb use deficits and sensory neglect in unilateral 6-OHDA-lesioned rats. Restor. Neurol. Neurosci. 13:1998;205-212.
21. Shults C.W., Kimber T., Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. NeuroReport. 7:1996;627-631.
22. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. Neurol. 124:1993;401-412.
23. Sullivan A.M., Opacka-Juffry J., Blunt S.B. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur. J. Neurosci. 10:1998;57-63.
24. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol. 367:1971;69-93.
25. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
26. Watson R. Jr, Wiegand S.J., Clough R.W., Hoffman G.E. Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides. 7:1986;155-159.
27. Williams L.R., Inouye G., Cummins V., Pelleymounter M.A. Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J. Pharmacol. Exp. Ther. 277:1996;1140-1151.
28. Winkler C., Sauer H., Lee C.S., Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16:1996;7206-7215.
29. Zetterstrom T., Herrera-Marschitz M., Ungerstedt U. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 376:1986;1-7.